Étude de phase 1b/2a du NVG-291 chez des sujets blessés à la moelle épinière
Une étude de phase 1b/2a randomisée, en double aveugle et contrôlée par placebo sur le NVG-291 chez des sujets blessés à la moelle épinière
A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
To evaluate the effect of NVG-291 on descending connectivity in subjects with subacute and chronic SCI (20 subjects per Cohort and results will be analyzed separately) using objective electrophysiological measures, in addition to clinical assessments. To evaluate safety and tolerability of NVG-291 in a SCI population, as measured by clinical assessments (Physical Examination, Vital Signs, ECG, etc.) as well as clinical laboratory measures. NOTE: Enrollment of the chronic cohort has been completed; approximately 20 individuals will be enrolled in the subacute group. For more information about the trial please visit www.connectscistudy.com.
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Phase
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Shirley Ryan AbilityLab
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- A subject must provide written informed consent in accordance with local regulations prior to initiation of any study-specific activities/procedures. A legally authorized representative (LAR) may be used to assist in signing the informed consent.
- Cervical spinal cord injury (SCI) resulting from acute physical trauma.
- Males and females.
- Age 18 to 75 years, inclusive.
- Cervical SCI, incomplete, with a neurological level of injury at C7 or higher.
- Had incomplete cervical SCI within the period from 1 year to 10 years inclusive (Chronic Cohort 1) OR within 20 days to 90 days inclusive (Subacute Cohort 2) at time of randomization.
- Chronic Cohort 1 only: Must be able to volitionally initiate at least one step on one leg (without body weight support).
- Must have a Walking Index for Spinal Cord Injury II (WISCI II) score as follows:
- Chronic Cohort 1: Less than or equal to Level 14.
- Subacute Cohort 2: Less than or equal to Level 10.
- Graded Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) Prehension Ability score/hand grip strength as follows:
- Chronic Cohort 1:
- Must have a score of at least 2 on at least one of the Prehension Ability grasp patterns of the GRASSP assessment in at least one upper extremity.
- Must have no more than one Prehension Ability grasp pattern score = 4 in the upper extremity satisfying the criterion above.
- Subacute Cohort 2:
- Must have some voluntary (nonzero) force measured by grip dynamometry in at least one upper extremity.
- Must have no more than one Prehension Ability grasp pattern score = 3 in at least one upper extremity.
- Must not have a Prehension Ability grasp pattern score = 4 in the upper extremity satisfying the criterion above.
- Presence of Motor Evoked Potentials (MEPs):
- Chronic Cohort 1: In two specific target muscle groups.
- Subacute Cohort 2: In one specific target muscle group.
- Must be fluent in English.
- Must be willing and able to comply with scheduled visits, all sample collections, and other trial procedures.
Exclusion Criteria:
- Nontraumatic SCI (e.g., due to infection, ischemia, metabolic abnormality, congenital abnormality, malignancy, radiation injury, surgical complications, or other disease process).
- SCI due to gunshot wound or penetrating injury.
- Two or more (noncontiguous) spinal cord lesions.
- MRI or CT evidence of anatomically complete spinal cord transection.
- Any form of ventilatory dependence.
- Any condition that precludes adequate clinical assessment of all four extremities, such as contracture, peripheral nerve injury, or amputation.
- History of uncontrolled seizures, or:
- Chronic Cohort 1: Any seizure within the last 6 months.
- Subacute Cohort 2: Any seizure occurring 1 week or more after the SCI.
- Metal implant in the head that is likely to interfere with MRI analysis.
- Pregnant or breastfeeding.
- Any neurological condition that is considered to interfere with performance or likely confound assessment, such as multiple sclerosis, stroke, or progressive syringomyelia.
- History of substance abuse within 12 months prior to screening, based on medical records or self-report.
- Evidence of spinal instability or persistent spinal stenosis and/or compression related to the initial trauma.
- Prior treatment with cell therapy delivered into the central nervous system (intrathecal or intraparenchymal).
- Severe neuropathic pain inadequately controlled by medication.
- Body mass index (BMI) > 40 kg/m2.
- Received botulinum toxin injection(s) in an upper or lower extremity muscle in the prior 6 months.
- Received 4-aminopyridine within 7 days of first dose.
- Prior treatment with a protein tyrosine phosphatase sigma (PTPσ) mimetic peptide.
- Intrathecal opioid use.
- Currently participating in an interventional clinical trial.
- Received a non-permitted medication within 5.5 half-lives or 7 days, whichever is longer, prior to randomization.
- Receiving any treatment intended to enhance neuroplasticity (e.g., electrical stimulation, acute intermittent hypoxia) at the time of consent or within 4 weeks of randomization, whichever is longer.
- Any implanted internal spinal cord stimulator.
- Currently receiving neuromuscular stimulation.
- Currently receiving vagal or phrenic nerve stimulation.
- Chronic Cohort 1 only: Any contraindication to baseline and on-study MRIs, such as:
- History of a cardiac pacemaker or pacemaker wires.
- Ferromagnetic metallic particles in the body.
- Baclofen pump.
- Vascular clips in the head.
- Prosthetic heart valves.
- Severe claustrophobia impeding ability to participate in an imaging study.
- Malignancy within 5 years prior to screening, except for non-melanoma skin cancers or cervical or breast ductal carcinoma in situ.
- History of medically significant hepatic disease or evidence of impaired liver function based on initial laboratory testing.
- Severe renal insufficiency, defined as eGFR < 30 mL/min/1.73m2.
- Any disease, concomitant injury (such as significant traumatic brain injury), or condition that could interfere with the performance or interpretation of the protocol-specified assessments, in the opinion of the investigator.
- Any other social or medical condition (e.g., uncontrolled diabetes, unstable hypertension) which, in the opinion of the investigator, would make the subject unsuitable for study participation.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: NVG-291 for SC Injection
NVG-291 administered by subcutaneous injection once daily for 12 weeks, with cetirizine pretreatment. |
A once daily injection |
|
Comparateur placebo: Placebo for SC Injection
Matching placebo administered by subcutaneous injection once daily for 12 weeks, with cetirizine pretreatment. |
A once daily injection |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Electrophysiological
Délai: 12 weeks
|
MEP amplitudes (corticospinal contribution) in key target muscle groups |
12 weeks
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
10mWT time
Délai: 12 weeks
|
Walking speed |
12 weeks
|
|
9-HPT time
Délai: 12 weeks
|
Upper extremity dexterity |
12 weeks
|
|
Dynamometry testing (pinch grip, Chronic cohort 1; hand grip, Subacute cohort 2)
Délai: 12 weeks
|
Recorded force |
12 weeks
|
|
Graded and Redefined Assessment of Strength, Sensibility, and Prehension Test
Délai: 12 weeks
|
Hand function Max Score 116 points |
12 weeks
|
|
Lower extremity motor score (LEMS)
Délai: 12 weeks
|
Lower extremity Max Score 50 points |
12 weeks
|
|
Upper extremity motor score (UEMS)
Délai: 12 weeks
|
Upper extremity Max Score 50 points |
12 weeks
|
|
Incidences of Treatment Emergent Adverse Events (Safety and Tolerability)
Délai: 16 Weeks
|
incidences of treatment emergent adverse events |
16 Weeks
|
|
Plasma Concentration of Study Drug
Délai: 12 Weeks
|
initial and steady state predose and peak plasma drug concentrations |
12 Weeks
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Les enquêteurs
Les enquêteurs
- Directeur d'études: Randall Kaye, M.D., NervGen Pharma
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Réel)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- NVG-291-201
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .